Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2012-11-19
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification and Characterization of Bone-related Genetic Variants in Families
NCT02762318
Clinical and Molecular Studies in Families With Inherited Eye Disease
NCT02771236
Study of Clinical and Molecular Manifestations of Genetic Disorders
NCT00001466
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders
NCT04399694
Clinical and Genetic Studies of VACTERL Association
NCT00766571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will include all genetic disorders from all ethnic backgrounds but Mendelian disease for which a gene mutation has already been identified will be excluded.
Evidence of Mendelian Transmission determined by fulfilling one of the following criteria:
Multiple affected family members (at least first degree relative with disease) History of consanguinity Severe disease in newborn in the absence of family history Sydromic disease in single individuals Congenital abnormality affecting major organ system(s) Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All genetic disorders are included
* All ethnic backgrounds are accepted
* Disease must be genetic with no evident environmental cause
* Evidence of Mendelian Transmission determined by fulfilling one of the following criteria:
* Multiple affected family members (at least first degree relative with disease)
* History of consanguinity
* Severe disease in newborn in the absence of family history
* Sydromic disease in single individuals
* Congenital abnormality affecting major organ system(s)
* Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension)
Exclusion Criteria
* Mendelian disease for which a gene mutation has already been identified
* Individuals for which a molecular diagnosis has already been established by alternative method
* Disease for which an environmental factor is most likely the cause
* Disease for which late age of onset rule out Mendelian transmission
* Common diseases for which late age of onset rule out Mendelian transmission
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hamad Medical Corporation
INDUSTRY
Weill Cornell Medical College in Qatar
OTHER
Weill Medical College of Cornell University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald Crystal, MD
Role: PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hamad Medical Corporation
Doha, , Qatar
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-00065 [JIRB]
Identifier Type: -
Identifier Source: org_study_id
12217/12
Identifier Type: OTHER
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.